Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes

被引:21
作者
Lundberg, LG
Hellstrom-Lindberg, E
Kanter-Lewensohn, L
Lerner, R
Palmblad, J [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Hematol, SE-14186 Stockholm, Sweden
[2] Karolinska Inst, Stockholm Soder Hosp, Dept Med, SE-14186 Stockholm, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Pathol, SE-14186 Stockholm, Sweden
[4] Karolinska Inst, Dept Med, Ctr Inflammat & Hematol Res, SE-14186 Stockholm, Sweden
关键词
Myelodysplastic syndrome; angiogenesis; international prognostic scoring system; apoptosis; CD34; endothelium;
D O I
10.1016/j.leukres.2005.07.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The International Prognostic Scoring System (IPSS), based on the number of cytopenias, percentage of bone marrow blasts and cytogenetics, is an important prognostic tool for patients with myelodysplastic syndrome (MDS). In addition, factors such as high bone marrow cellularity and lactate dehydrogenase levels have been associated with an adverse outcome, spontaneously and after chemotherapy. Recently, increased bone marrow angiogenesis, measured as, e.g. microvascular density (MVD), was reported to be more intense in high-risk than in low-risk MDS. To assess the prognostic role of MVD in MDS, a cohort of 56 patients, thoroughly investigated for various clinical and morphological parameters, were followed-up for survival >= 60 months after the diagnostic analysis. As a group MDS patients had higher MVD compared to healthy controls (p < 0.02). The highest median MVD value was observed in the RAEB group, but there was no overall significant difference between the FAB groups. No significant correlations were observed between MVD and peripheral blood counts, bone marrow cellularity, percentage of bone marrow blasts and CD34 positive cells, apoptotic index (TUNEL), proliferation index (MIB-1), erythroid index, FAB group and IPSS score. MVD was not correlated to overall survival. In contrast, bone marrow blast count < 5%, low or normal cellularity, as well as a high erythroid index, indicated a favorable survival. Thus, our data do not support an important prognostic role of angiogenesis, reflected by microvessel density, in the myelodysplastic syndromes. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 31 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]   Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, HM ;
Estey, EH ;
Giles, FJ ;
Verstovsek, S ;
Manshouri, T ;
Gidel, C ;
O'Brien, S ;
Keating, MJ ;
Albitar, M .
CANCER, 2002, 95 (09) :1923-1930
[3]  
AUL C, 1992, LEUKEMIA, V6, P52
[4]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[5]   Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice [J].
Bråkenhielm, E ;
Cao, RH ;
Gao, BH ;
Angelin, B ;
Cannon, B ;
Parini, P ;
Cao, YH .
CIRCULATION RESEARCH, 2004, 94 (12) :1579-1588
[6]   Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia [J].
Brunner, B ;
Gunsilius, E ;
Schumacher, P ;
Zwierzina, H ;
Gastl, G ;
Stauder, R .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2002, 11 (01) :119-125
[7]   In vitro evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach [J].
Campioni, D ;
Punturieri, M ;
Bardi, A ;
Moretti, S ;
Tammiso, E ;
Lanza, F ;
Castoldi, G .
LEUKEMIA RESEARCH, 2004, 28 (01) :9-17
[8]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[9]   No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes:: better outcome in patients with less proliferative disease [J].
Hast, R ;
Hellström-Lindberg, E ;
Ohm, L ;
Björkholm, M ;
Celsing, F ;
Dahl, JM ;
Dybedal, I ;
Gahrton, G ;
Lindberg, G ;
Lerner, R ;
Linder, O ;
Löfvenberg, E ;
Nilsson-Ehle, H ;
Paul, C ;
Samuelsson, J ;
Tangen, JM ;
Tidefelt, U ;
Turesson, I ;
Wahlin, A ;
Wallvik, J ;
Winquist, I ;
Öberg, G ;
Bernell, P .
LEUKEMIA, 2003, 17 (09) :1827-1833
[10]   Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes:: serum thrombopoietin levels and bone marrow morphology [J].
Hellström-Lindberg, E ;
Kanter-Lewensohn, L ;
Nichol, J ;
Öst, Å .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :966-973